NCT05576272View on ClinicalTrials.gov

A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

460

Participants

Timeline

Start Date

May 19, 2022

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2024

Conditions
Nasopharyngeal Carcinoma
Interventions
DRUG

QL1706

5 mg/kg#D1#Q3W IV, 4-6 cycles

DRUG

Carrelizumab

200mg#D1#Q3W IV, 4-6 cycles

DRUG

Gemcitabine

1000mg/m2#D1\&D8#Q3W IV, 4-6 cycles

DRUG

Cisplatin

80mg/m2#D1#Q3W IV, 4-6 cycles

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY